J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Nvidia Options Price in $280 Billion Earnings Swing 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Tesla Raises Cybertruck Prices by $5,000 in US 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Meta, U.S. States Discuss Settlement in Teen Addiction Trial 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Trump Buys SpaceX Shares After Record IPO 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Add as a preferred source on Google
TUCSON, Ariz., April 27, 2018 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that it will report its financial results for the quarter ended March 31, 2018 after the market close on Thursday, May 10. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
| Conference Call & Webcast Details | ||
| Date: | Thursday, May 10 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | 866-548-4713 | |
| International: | 323-794-2093 | |
| Conference ID: | 5477857 | |
| Webcast: | http://public.viavid.com/index.php?id=129155 | |
About HTG:
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
[email protected]
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
[email protected]
